206193-18-2

Basic information

• Product Name: (2R)-3-Bromo-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
• Synonyms: (2R)-3-Bromo-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide;(R)-3-bromo-2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide
• CAS NO: 206193-18-2
• Molecular Formula: C₁₁H₁₀BrF₃N₂O₄
• Molecular Weight: 371.108
• Mol File: 206193-18-2.mol
• Article Data: 16

Chemical Properties

• Melting Point: 100-101.5 °C
• Boiling Point: 491.7 °C at 760 mmHg
• Flash Point: 251.2 °C
• Appearance: /
• Density: 1.753
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 11.68±0.29(Predicted)
• CAS DataBase Reference: (2R)-3-Bromo-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide(CAS DataBase Reference)
• NIST Chemistry Reference: (2R)-3-Bromo-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide(206193-18-2)
• EPA Substance Registry System: (2R)-3-Bromo-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide(206193-18-2)

Safety Data

• Hazardous Substances Data: 206193-18-2(Hazardous Substances Data)

Usage

Uses

(2R)-3-Bromo-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide is an intermediate in the synthesis of 4-Desacetamido-4-fluoro Andarine (D289530), a Selective Androgen Receptor Modulator (SARM) that has potential use for treatment of androgen related diseases such as muscle wasting and osteoporosis.

Upstream product

• 81026-68-8 (R)-3-bromo-2-hydroxy-2-methylpropanoic acid 
• 393-11-3 4-nitro-3-(trifluoromethyl)benzeneamine 
• 261904-39-6 (2R)-3-bromo-2-hydroxy-2-methylpropanoic acid 
• 1010396-30-1 (R)-3-bromo-2-hydroxy-2-methylpropanoyl chloride 

Downstream Products

• 401900-41-2 3-(4-fluoro-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide 
• 1245370-20-0 (S)-tert-butyl-2-(2-(2-(4-(2-hydroxy-2-methyl-3-(4-nitro-3-(trifluoromethyl)phenylamino)-3-oxopropoxy)benzamido)ethoxy)ethoxy)ethylcarbamate 
• 1245370-28-8 (S)-tert-butyl-2,2',2-(10-(1-(4-(2-hydroxy-2-methyl-3-(4-nitro-3-(trifluoromethyl)phenylamino)-3-oxopropoxy)phenyl)-1,12-dioxo-5,8-dioxa-2,11-diazatridecan-13-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate 
• 476314-39-3 2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-3-[4-(2,2,2-trifluoro-acetylamino)-phenylsulfanyl]-propionamide 
• 476314-38-2 3-[4-(2-chloro-acetylamino)-phenylsulfanyl]-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide 
• 476314-40-6 2-hydroxy-3-(4-methanesulfonylamino-phenylsulfanyl)-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide 
• 476314-37-1 3-(4-acetylamino-phenylsulfanyl)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide 
• 885324-25-4 Ostarine 

Relevant articles and documents

SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF

This invention is directed to selective androgen receptor degrader (SARD) compounds including heterocyclic rings and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer

We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-Antagonists that exert broad-scope AR antagonism. Pharmacological ev

METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs

The present invention is directed to methods of treating, preventing, suppressing and/or inhibiting urological disorders such as urinary incontinence including stress urinary incontinence and pelvic-floor disorders by administering a SARM compound of the invention.